Citations (131)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Dennis V. Parke. (1997) A History of Drug Metabolism in the United Kingdom. Drug Metabolism Reviews 29:3, pages 801-851.
Read now
Read now
M. J. Ackland. (1993) Correlation between site specificity and electrophilic frontier values in the metabolic hydroxylation of biphenyl, di-aromatic and CYP2D6 substrates: a molecular modelling study. Xenobiotica 23:10, pages 1135-1144.
Read now
Read now
D. M. Pierce. (1990) A review of the clinical pharmacokinetics and metabolism of the α1-adrenoceptor antagonist indoramin. Xenobiotica 20:12, pages 1357-1367.
Read now
Read now
G. Gordon Gibson. (1989) Comparative aspects of the mammalian cytochrome P450 IV gene family. Xenobiotica 19:10, pages 1123-1148.
Read now
Read now
Michael F. W. Festing & Elliot S. Vesell. (1987) Genetic Factors in Toxicology: Implications for Toxicological Screening. CRC Critical Reviews in Toxicology 18:1, pages 1-26.
Read now
Read now
Elliot S. Vesell. (1986) Polymorphisms of antipyrine and theophylline metabolism in man: Molecular and clinical implications. Xenobiotica 16:5, pages 401-420.
Read now
Read now
F. Peter Guengerich, Daniel C. Liebler & Donald L. Reed. (1985) Enzymatic activation of chemicals to toxic metabolites. CRC Critical Reviews in Toxicology 14:3, pages 259-307.
Read now
Read now
GilbertS. Omenn. (1984) Advances in Genetics and Immunology: The Importance of Basic Research to Prevention of Occupational Diseases. Archives of Environmental Health: An International Journal 39:3, pages 173-182.
Read now
Read now
Peter G. Dayton & James E. Sanders. (1983) Dose-Dependent Pharmacokinetics: Emphasis on Phase I Metabolism. Drug Metabolism Reviews 14:3, pages 347-405.
Read now
Read now
Articles from other publishers (122)
Daniel W. Nebert & Ge Zhang. 2019. Emery and Rimoin's Principles and Practice of Medical Genetics and Genomics. Emery and Rimoin's Principles and Practice of Medical Genetics and Genomics
445
486
.
F. Peter Guengerich. 2014. Fifty Years of Cytochrome P450 Research. Fifty Years of Cytochrome P450 Research
17
41
.
Yoko TanakaLuis A. RohdeLing JinPeter D. FeldmanHimanshu P. Upadhyaya. (2013) A Meta-analysis of the Consistency of Atomoxetine Treatment Effects in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder from 15 Clinical Trials Across Four Geographic Regions. Journal of Child and Adolescent Psychopharmacology 23:4, pages 262-270.
Crossref
Crossref
Daniel W. Nebert & Elliot S. Vesell. 2013. Emery and Rimoin's Principles and Practice of Medical Genetics. Emery and Rimoin's Principles and Practice of Medical Genetics
1
27
.
M Vincent-Viry, S Deshayes, O Mothe, G Siest & M M Galteau. (1988) Hydroxylation of Debrisoquine Using Perfused Liver Isolated from Sprague Dawley and DA Rats: Comparison With In-vivo Results. Journal of Pharmacy and Pharmacology 40:10, pages 694-700.
Crossref
Crossref
S G AL-DABBAGH, J R IDLE & R L SMITH. (1981) Animal modelling of human polymorphic drug oxidation—the metabolism of debrisoquine and phenacetin in rat inbred strains. Journal of Pharmacy and Pharmacology 33:1, pages 161-164.
Crossref
Crossref
F. Peter Guengerich, Zhongmei Tang, Qian Cheng & S. Giovanna Salamanca-Pinzón. (2011) Approaches to deorphanization of human and microbial cytochrome P450 enzymes. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 1814:1, pages 139-145.
Crossref
Crossref
Nicole M. Walley, Paola Nicoletti & David B. Goldstein. 2010. Vogel and Motulsky's Human Genetics. Vogel and Motulsky's Human Genetics
635
647
.
John R. Foster. 2009. General, Applied and Systems Toxicology. General, Applied and Systems Toxicology.
Mateus Fuchshuber-Moraes, Jamila A. Perini, Dieter Rosskopf & Guilherme Suarez-Kurtz. (2009) Exploring warfarin pharmacogenomics with the extreme-discordant-phenotype methodology: impact of FVII polymorphisms on stable anticoagulation with warfarin. European Journal of Clinical Pharmacology 65:8, pages 789-793.
Crossref
Crossref
Helena Buzková, Kristina Pechandová, Ondřej Slanař & František Perlík. (2007) Frequency of single nucleotide polymorphisms of CYP2D6 in the Czech population. Cell Biochemistry and Function 26:1, pages 76-81.
Crossref
Crossref
John Caldwell. (2006) Drug metabolism and pharmacogenetics: the British contribution to fields of international significance. British Journal of Pharmacology 147:S1, pages S89-S99.
Crossref
Crossref
Aiming Yu & Robert Haining. 2003. Drug Metabolizing Enzymes. Drug Metabolizing Enzymes
375
419
.
Anthony Y. H. Lu, Regina W. Wang & Jiunn H. Lin. (2003) Cytochrome P450 In Vitro Reaction Phenotyping: A Re-evaluation of Approaches Used for P450 Isoform Identification. Drug Metabolism and Disposition 31:4, pages 345-350.
Crossref
Crossref
Aiming Yu, Byron M. Kneller, Allan E. Rettie & Robert L. Haining. (2002) Expression, Purification, Biochemical Characterization, and Comparative Function of Human Cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 Allelic Isoforms. Journal of Pharmacology and Experimental Therapeutics 303:3, pages 1291-1300.
Crossref
Crossref
Imad H. Hanna, Mi-Sook Kim & F.Peter Guengerich. (2001) Heterologous Expression of Cytochrome P450 2D6 Mutants, Electron Transfer, and Catalysis of Bufuralol Hydroxylation: The Role of Aspartate 301 in Structural Integrity. Archives of Biochemistry and Biophysics 393:2, pages 255-261.
Crossref
Crossref
I. Stoilov, I. Jansson, M. Sarfarazi & J.B. Schenkman. (2001) Roles of Cytochrome P450 in Development. Drug Metabolism and Drug Interactions 18:1.
Crossref
Crossref
Daniel W Nebert. (2000) Extreme discordant phenotype methodology: an intuitive approach to clinical pharmacogenetics. European Journal of Pharmacology 410:2-3, pages 107-120.
Crossref
Crossref
Mark R. Hadley, Patrick Camilleri & Andrew J. Hutt. (2000) Enantiospecific analysis by capillary electrophoresis: Applications in drug metabolism and pharmacokinetics. Electrophoresis 21:10, pages 1953-1976.
Crossref
Crossref
Jeanette J. McCarthy & Rolf Hilfiker. (2000) The use of single-nucleotide polymorphism maps in pharmacogenomics. Nature Biotechnology 18:5, pages 505-508.
Crossref
Crossref
Simon Ball & Neil Borman. (1998) Pharmacogenetics and drug metabolism. Nature Biotechnology 16:S2, pages 4-5.
Crossref
Crossref
Patrick W. KleynElliot S. Vesell. (1998) Genetic Variation as a Guide to Drug Development. Science 281:5384, pages 1820-1821.
Crossref
Crossref
Charles V. Vorhees, Tracy M. Reed, Mary A. Schilling, J.Edward Fisher, Mary S. Moran, Gregg D. Cappon & Daniel W. Nebert. (1998) Cyp2d1 Polymorphism in Methamphetamine-Treated Rats. Neurotoxicology and Teratology 20:3, pages 265-273.
Crossref
Crossref
Simon Ball & Neil Borman. (1997) Pharmacogenetics and drug metabolism. Nature Biotechnology 15:10, pages 925-926.
Crossref
Crossref
DANIEL W. NEBERT, ROSS A. MCKINNON & ALVARO PUGA. (1996) Human Drug-Metabolizing Enzyme Polymorphisms: Effects on Risk of Toxicity and Cancer. DNA and Cell Biology 15:4, pages 273-280.
Crossref
Crossref
Jan Braess, Eberhard Schleyer, Bernhard Ramsauer, Michael Unterhalt, Cornelia Kaufmann, Sabine Wilde, Martin Schüssller & Wolfgang Hiddemann. 1996. Acute Leukemias V. Acute Leukemias V
32
40
.
G. Gordon Gibson & Paul SkettG. Gordon Gibson & Paul Skett. 1994. Introduction to Drug Metabolism. Introduction to Drug Metabolism
180
216
.
G. Gordon Gibson & Paul SkettG. Gordon Gibson & Paul Skett. 1994. Introduction to Drug Metabolism. Introduction to Drug Metabolism
133
156
.
Winston W. Shen. (1995) Cytochrome P450 Monooxygenases and Interactions of Psychotropic Drugs: A Five-Year Update. The International Journal of Psychiatry in Medicine 25:3, pages 277-290.
Crossref
Crossref
Th. Wolff & M. Strecker. (1992) Endogenous and exogenous factors modifying the activity of human liver cytochrome P-450 enzymes. Experimental and Toxicologic Pathology 44:5, pages 263-271.
Crossref
Crossref
F. Peter Guengerich. (1992) Metabolic activation of carcinogens. Pharmacology & Therapeutics 54:1, pages 17-61.
Crossref
Crossref
P. Del Santo, G. Moneti, M. Salvadori, C. Saltutti, A. Delle Rose & P. Dolara. (1991) Levels of the adducts of 4-aminobiphenyl to hemoglobin in control subjects and bladder carcinoma patients. Cancer Letters 60:3, pages 245-251.
Crossref
Crossref
MG Ladona, B Lindstrom, C Thyr, P Dun‐Ren & A Rane. (2012) Differential foetal development of the O‐ and N‐demethylation of codeine and dextromethorphan in man.. British Journal of Clinical Pharmacology 32:3, pages 295-302.
Crossref
Crossref
J Turgeon, WE Evans, MV Relling, GR Wilkinson & DM Roden. (2012) Phenotypic debrisoquine 4‐hydroxylase activity among extensive metabolizers is unrelated to genotype as determined by the Xba‐I restriction fragment length polymorphism.. British Journal of Clinical Pharmacology 32:3, pages 283-288.
Crossref
Crossref
J. Desmeules & P. Dayer. (1991) Rôle du polymorphisme de l'oxydation type débrisoquine dans la biotransformation de la codéine en morphine et dans son effet antalgique. Douleur et Analgésie 4:3, pages 79-86.
Crossref
Crossref
Daniel W. Nebert. (1991) Identification of genetic differences in drug metabolism: Prediction of individual risk of toxicity or cancer. Hepatology 14:2, pages 398-401.
Crossref
Crossref
Dorie W. Schwertz. (1991) Basic Principles of Pharmacologic Action. Nursing Clinics of North America 26:2, pages 245-262.
Crossref
Crossref
F.P. Guengerich. (1991) Reactions and significance of cytochrome P-450 enzymes. Journal of Biological Chemistry 266:16, pages 10019-10022.
Crossref
Crossref
Gilbert S. Omenn. (1991) Future research directions in cancer ecogenetics. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 247:2, pages 283-291.
Crossref
Crossref
Daniel W. Nebert. (1991) Role of genetics and drug metabolism in human cancer risk. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 247:2, pages 267-281.
Crossref
Crossref
Elliot S. Vesell. (1991) Genetic and environmental factors causing variation in drug response. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 247:2, pages 241-257.
Crossref
Crossref
Yasuhiro Masubuchi, Shoichi Fujita, Masato Chiba, Noriko Kagimoto, Shin Umeda & Tokuji Suzuki. (1991) Impairment of debrisoquine 4-hydroxylase and related monooxygenase activities in the rat following treatment with propranolol. Biochemical Pharmacology 41:6-7, pages 861-865.
Crossref
Crossref
Jens Huober, Barbara Bertram, Edgar Petru, Manfred Kaufmann & Dietrich Schmähl. (1991) Metabolism of debrisoquine and susceptibility to breast cancer. Breast Cancer Research and Treatment 18:1, pages 43-48.
Crossref
Crossref
H. W. Goedde & H.-G. Benkmann. 1991. Genetics of the Hungarian Population. Genetics of the Hungarian Population
169
196
.
S. B. Seredenin, I. V. Rybina, T. G. Khlopushina & V. P. Zherdev. (1990) Determination of oxidation phenotype in inbred C57Bl/6 and BALB/C mice. Bulletin of Experimental Biology and Medicine 110:5, pages 1505-1507.
Crossref
Crossref
A.M. Monro. (1990) Interspecies comparisons in toxicology: The utility and futility of plasma concentrations of the test substance. Regulatory Toxicology and Pharmacology 12:2, pages 137-160.
Crossref
Crossref
Gregory L. Kedderis. 1990. Toxic Interactions. Toxic Interactions
31
60
.
Frank J. Gonzalez & Daniel W. Nebert. (1990) Evolution of the P450 gene superfamily:. Trends in Genetics 6, pages 182-186.
Crossref
Crossref
Frank J. Gonzalez. (1990) Molecular genetics of the P-450 superfamily. Pharmacology & Therapeutics 45:1, pages 1-38.
Crossref
Crossref
PR Jackson, GT Tucker & HF Woods. (2012) Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism‐histograms and probit plots.. British Journal of Clinical Pharmacology 28:6, pages 647-653.
Crossref
Crossref
T Aoyama, S Yamano, D J Waxman, D P Lapenson, U A Meyer, V Fischer, R Tyndale, T Inaba, W Kalow, H V Gelboin & F J Gonzalez. (1989) Cytochrome P-450 hPCN3, a Novel Cytochrome P-450 IIIA Gene Product That Is Differentially Expressed in Adult Human Liver. Journal of Biological Chemistry 264:18, pages 10388-10395.
Crossref
Crossref
Maryse Gueguen, Ana Maria Yamamoto, Oliver Bernard & Fernando Alvarez. (1989) Anti-liver kidney microsome antibody type 1 recognizes human cytochrome P450 db1. Biochemical and Biophysical Research Communications 159:2, pages 542-547.
Crossref
Crossref
John A. Oates & Alastair J.J. Wood. (1989) The Regulation of Discovery and Drug Development. New England Journal of Medicine 320:5, pages 311-312.
Crossref
Crossref
Jacques Turgeon, Christian Funck-Brentano, Holly T. Gray & Dan M. Roden. (1989) Improved high-performance liquid chromatographic assay for encainide and its metabolites in human body fluids. Journal of Chromatography B: Biomedical Sciences and Applications 490, pages 165-174.
Crossref
Crossref
Elliot S. Vesell. (1989) Pharmacogenetic perspectives gained from twin and family studies. Pharmacology & Therapeutics 41:3, pages 535-552.
Crossref
Crossref
Michael H. Skinner, Leslie Lenert & Terrence F. Blaschke. (1989) Theophylline toxicity subsequent to ranitidine administration: A possible drug-drug interaction. The American Journal of Medicine 86:1, pages 129-132.
Crossref
Crossref
Semra ŞardaŞ, Ali Esat Karakaya & Jeffrey R. Idle. (2008) Are the traits for drug acetylation and oxldation co-inherited?. Clinical Genetics 34:2, pages 143-144.
Crossref
Crossref
Ulrich M. Zanger, Francis Vilbois, James P. Hardwick & Urs A. Meyer. (2002) Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man. Biochemistry 27:15, pages 5447-5454.
Crossref
Crossref
E J Calabrese. (1988) Comparative biology of test species.. Environmental Health Perspectives 77, pages 55-62.
Crossref
Crossref
FRANK J. GONZALEZ, BALTHAZAR J. SCHMID, MORIO UMENO, O. WESLEY MCBRIDE, JAMES P. HARDWICK, URS A. MEYER, HARRY V. GELBOIN & JEFFREY R. IDLE. (1988) Human P450PCN1: Sequence, Chromosome Localization, and Direct Evidence through cDNA Expression That P450PCN1 Is Nifedipine Oxidase. DNA 7:2, pages 79-86.
Crossref
Crossref
J. M. Braganza, A. Thomas & A. Robinson. (1988) Antioxidants to treat chronic pancreatitis in childhood?. International journal of pancreatology 3:2-3, pages 209-216.
Crossref
Crossref
Frank J. Gonzalez, Radek C. Skodat, Shioko Kimura, Morio Umeno, Ulrich M. Zanger, Daniel W. Nebert, Harry V. Gelboin, James P. Hardwick & Urs A. Meyer. (1988) Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 331:6155, pages 442-446.
Crossref
Crossref
Frank J. Gonzalez, Francis Vilbois, James P. Hardwick, O.Wesley McBride, Daniel W. Nebert, Harry V. Gelboin & Urs A. Meyer. (1988) Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22. Genomics 2:2, pages 174-179.
Crossref
Crossref
Harry V. Gelboin, Frank J. Gonzalez, Sang S. Park, Junji Sagara & Narayana Battula. 1988. Chemical Carcinogenesis. Chemical Carcinogenesis
3
15
.
Edward J. Calabrese. 1988. Carcinogen Risk Assessment. Carcinogen Risk Assessment
115
122
.
Daniel W. Nebert. 1988. Phenotypic Variation in Populations. Phenotypic Variation in Populations
45
64
.
Oscar Torres-Alanís, Lourdes Garza-Ocañas & Alfredo Piñeyro-López. 1989. Cell Function and Disease. Cell Function and Disease
189
198
.
C. LIBERSA, J. CARON, P. Bechtel, S. KACET, J. DAGANO, R. ROUEX, X. MARCHAND, B. DUPUIS & J. LEKIEFFRE. (2008) Interest and Limitations of Phenotype Determination of Hydroxylation Ability in Patients Treated with Propafenone. Journal of Electrophysiology 1:5, pages 466-474.
Crossref
Crossref
FRANK J. GONZALEZ, TAMIHIDE MATSUNAGA, KIYOSHI NAGATA, URS A. MEYER, DANIEL W. NEBERT, JULLIA PASTEWKA, CHRISTINE A. KOZAK, JAMES GILLETTE, HARRY V. GELBOIN & JAMES P. HARDWICK. (1987) Debrisoquine 4-Hydroxylase: Characterization of a New P450 Gene Subfamily, Regulation, Chromosomal Mapping, and Molecular Analysis of the DA Rat Polymorphism. DNA 6:2, pages 149-161.
Crossref
Crossref
J. R. Woodworth, S. R. K. Dennis, L. Moore & K. S. Rotenberg. (1987) The Polymorphic Metabolism of Dextromethorphan. The Journal of Clinical Pharmacology 27:2, pages 139-143.
Crossref
Crossref
Pitambar Somani, Theodore D. FrakerJrJr & Peter N. Temesy-Armos. (1987) Pharmacokinetic Implications of Lorcainide Therapy in Patients With Normal and Depressed Cardiac Function. The Journal of Clinical Pharmacology 27:2, pages 122-132.
Crossref
Crossref
Thomas F. Woolf & Ronald A. Jordan. (2013) Basic Concepts in Drug Metabolism: Part I. The Journal of Clinical Pharmacology 27:1, pages 15-17.
Crossref
Crossref
D. M. Pierce, S. E. Smith & R. A. Franklin. (1987) The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine. European Journal of Clinical Pharmacology 33:1, pages 59-65.
Crossref
Crossref
I. Sz�r�dy & A. S�nta. (1987) Drug hydroxylator phenotype in Hungary. European Journal of Clinical Pharmacology 32:3, pages 325-325.
Crossref
Crossref
M. Eichelbaum. 1987. Funktion und Funktionsdiagnostik der Leber. Funktion und Funktionsdiagnostik der Leber
145
160
.
Edward J. Calabrese. (1986) Animal Extrapolation and the Challenge of Human Heterogeneity. Journal of Pharmaceutical Sciences 75:11, pages 1041-1046.
Crossref
Crossref
D. P. Agarwal & H. W. Goedde. (1986) Pharmacogenetics and ecogenetics. Experientia 42:10, pages 1148-1154.
Crossref
Crossref
S. LOCHE, ARLEEN B. RIFKIND, ELIZABETH STONER, A. H. CONNEY & MARIA I. NEW. (2008) ANTIPYRINE CLEARANCE IN CONGENITAL ADRENAL HYPERPLASIA. Clinical Endocrinology 25:3, pages 233-239.
Crossref
Crossref
J Gut, T Catin, P Dayer, T Kronbach, U Zanger & U A Meyer. (1986) Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol.. Journal of Biological Chemistry 261:25, pages 11734-11743.
Crossref
Crossref
Evelyne Jacqz, Stephen D. Hall & Robert A. Branch. (1986) Genetically determined polymorphisms in drug oxidation. Hepatology 6:5, pages 1020-1032.
Crossref
Crossref
C.R. Wolf. (1986) Cytochrome P-450s: polymorphic multigene families involved in carcinogen activation. Trends in Genetics 2, pages 209-214.
Crossref
Crossref
G. Gordon Gibson & Paul SkettG. Gordon Gibson & Paul Skett. 1986. Introduction to Drug Metabolism. Introduction to Drug Metabolism
199
238
.
G. Gordon Gibson & Paul SkettG. Gordon Gibson & Paul Skett. 1986. Introduction to Drug Metabolism. Introduction to Drug Metabolism
147
174
.
S. B. Seredenin, Yu. A. Blednov, B. A. Badyshtov & N. M. Shevchenko. 1986. Drug Dependence and Emotional Behavior. Drug Dependence and Emotional Behavior
49
77
.
MW Teunissen, GJ Bruining, BM De Jongh, EW Tenkate‐Westerhof & DD Breimer. (2012) Antipyrine clearance and metabolite formation in children with congenital adrenal hyperplasia.. British Journal of Clinical Pharmacology 20:6, pages 703-706.
Crossref
Crossref
C. Zekorn, G. Achtert, H. J. Hausleiter, C. H. Moon & M. Eichelbaum. (1985) Pharmacokinetics of N-propylajmaline in relation to polymorphic sparteine oxidation. Klinische Wochenschrift 63:22, pages 1180-1186.
Crossref
Crossref
CH Gleiter, G Aichele, E Nilsson, N Hengen, KH Antonin & PR Bieck. (2012) Discovery of altered pharmacokinetics of CGP 15 210 G in poor hydroxylators of debrisoquine during early drug development.. British Journal of Clinical Pharmacology 20:1, pages 81-84.
Crossref
Crossref
L M Distlerath, P E Reilly, M V Martin, G G Davis, G R Wilkinson & F P Guengerich. (1985) Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism.. Journal of Biological Chemistry 260:15, pages 9057-9067.
Crossref
Crossref
Edward J. Calabrese. (1985) Uncertainty factors and interindividual variation. Regulatory Toxicology and Pharmacology 5:2, pages 190-196.
Crossref
Crossref
David B. Jack. (2008) FACTORS CONTRIBUTING TO VARIABILITY IN DRUG PHARMACOKINETICS. III. METABOLISM. Journal of Clinical Pharmacy and Therapeutics 10:1, pages 25-43.
Crossref
Crossref
H H Zhou, Y P Chan, K Arnold & M Sun. (1985) Single-dose pharmacokinetics of ceftriaxone in healthy Chinese adults. Antimicrobial Agents and Chemotherapy 27:2, pages 192-196.
Crossref
Crossref
F. -A. Wiesel, J. Raaflaub & R. Kettler. (1985) Pharmacokinetics of oral moclobemide in healthy human subjects and effects on MAO-activity in platelets and excretion of urine monoamine metabolites. European Journal of Clinical Pharmacology 28:1, pages 89-95.
Crossref
Crossref
M. Eichelbaum & N. M. Woolhouse. (1985) Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans. European Journal of Clinical Pharmacology 28:1, pages 79-83.
Crossref
Crossref
U. A. Meyer, P. Dayer, J. Gut & T. Kronbach. 1985. Trends in Hepatology. Trends in Hepatology
103
108
.
P. H. Bach & J. W. Bridges. 1986. Receptors and Other Targets for Toxic Substances. Receptors and Other Targets for Toxic Substances
173
188
.
J. A. Calvete, J.L.M. Donegan, R.J. Hayes, N.S. Oates & T.P. Sloan. (1984) Genetic heterogeneity of histamine H2-receptors in the mouse vas deferens. British Journal of Pharmacology 83:3, pages 723-731.
Crossref
Crossref
M. J. S. Langman. (1984) The Clinical Significance of Retarded Hepatic Drug Metabolism. Annals of Saudi Medicine 4:2, pages 181-182.
Crossref
Crossref
MV Rudorfer, EA Lane, WH Chang, MD Zhang & WZ Potter. (2012) Desipramine pharmacokinetics in Chinese and Caucasian volunteers.. British Journal of Clinical Pharmacology 17:4, pages 433-440.
Crossref
Crossref
A. K�pfer & R. Preisig. (1984) Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man. European Journal of Clinical Pharmacology 26:6, pages 753-759.
Crossref
Crossref
D. M. Roden, T. Wang, R. L. Woosley, A. J. J. Wood, R. A. Branch, A. Küpfer & G. R. Wilkinson. 1984. Pharmacokinetics. Pharmacokinetics
217
234
.
Douwe D. Breimer, Nico P. E. Vermeulen, Meindert Danhof, Michiel W. E. Teunissen, Rolf P. Joeres & Martin van der Graaff. 1984. Pharmacokinetics. Pharmacokinetics
191
216
.
F. B. Daniel, G. D. Stoner & H. A. J. Schut. 1984. Individual Susceptibility to Genotoxic Agents in the Human Population. Individual Susceptibility to Genotoxic Agents in the Human Population
177
199
.
Philip P. Wang, Philippe Beaune, Laurence S. Kaminsky, Ghazi A. Dannan, Fred F. Kadlubar, Dominique Larrey & F. Peter Guengerich. (2002) Purification and characterization of six cytochrome P-450 isozymes from human liver microsomes. Biochemistry 22:23, pages 5375-5383.
Crossref
Crossref
JoanM. Braganza. (1983) PANCREATIC DISEASE: A CASUALTY OF HEPATIC "DETOXIFICATION"?. The Lancet 322:8357, pages 1000-1003.
Crossref
Crossref
Peter J. Meier, Heinz K. Mueller, Bernhard Dick & Urs A. Meyer. (1983) Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation. Gastroenterology 85:3, pages 682-692.
Crossref
Crossref
M Eichelbaum, L Bertilsson & J Sawe. (2012) Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine.. British Journal of Clinical Pharmacology 15:3, pages 317-321.
Crossref
Crossref
Adrian Küpfer, Sabah G. Al-Dabbagh, James C. Ritchie, Jeffrey R. Idle & Robert L. Smith. (1982) Spectral binding studies of the polymorphically metabolized drugs debrisoquine, sparteine and phenformin by cytochrome P-450 of normal and hydroxylation deficient rat strains. Biochemical Pharmacology 31:20, pages 3193-3199.
Crossref
Crossref
R.H. Waring, S.C. Mitchell, R.R. Shah, J.R. Idle & R.L. Smith.. (1982) Polymorphic sulphoxidation of S-carboxymethyl-L-cysteine in man. Biochemical Pharmacology 31:19, pages 3151-3154.
Crossref
Crossref
. (2012) COMMUNICATIONS. British Journal of Pharmacology 76:S1.
Crossref
Crossref
Werner Kalow. (1982) Metabolism of psychoactive drugs. Progress in Neuro-Psychopharmacology and Biological Psychiatry 6:4-6, pages 615-621.
Crossref
Crossref
B. K. Tang, W. Kalow, L. Endrenyi & F. Y. Chan. (1982) An assessment of short-cut procedures for studying drug metabolism in vivo using amobarbital as a model drug. European Journal of Clinical Pharmacology 22:3, pages 229-233.
Crossref
Crossref
J. Caldwell, I. A. Cotgreave, C. A. Lawrie & T. J. Monks. 1982. Theophylline and other Methylxanthines / Theophyllin und andere Methylxanthine. Theophylline and other Methylxanthines / Theophyllin und andere Methylxanthine
159
167
.
D. D. Breimer. 1982. New Toxicology for Old. New Toxicology for Old
162
178
.
M. R. Hetzel, M. Law, E. E. Keal, T. P. Sloan, J. R. Idle & R. L. Smith. 1982. Cellular Biology of the Lung. Cellular Biology of the Lung
457
470
.
Curtis C. Harris, Benjamin F. Trump, Roland Grafstrom & Herman Autrup. (2004) Differences in Metabolism of Chemical Carcinogens in Cultured Human Epithelial Tissues and Cells. Journal of Cellular Biochemistry 18:3, pages 285-294.
Crossref
Crossref
D W Nebert. (1981) Clinical pharmacology. Possible clinical importance of genetic differences in drug metabolism.. BMJ 283:6290, pages 537-542.
Crossref
Crossref
Michel Eichelbaum. (1981) Polymorphism of drug oxidation in man: novel findings. Trends in Pharmacological Sciences 2, pages 31-34.
Crossref
Crossref
. (1980) Proceedings of the Thoracic Society. Thorax 35:9, pages 708-720.
Crossref
Crossref
R.R. Shah, N.S. Oates, J.R. Idle & R.L. Smith. (1980) GENETIC IMPAIRMENT OF PHENFORMIN METABOLISM. The Lancet 315:8178, pages 1147.
Crossref
Crossref
E.A. Edlinger, J.J. Benichou & B. Labrune. (1980) POSITIVE EHRLICHIA CANIS SEROLOGY IN KAWASAKI DISEASE. The Lancet 315:8178, pages 1146-1147.
Crossref
Crossref
DANIEL W. NEBERT. 1980. Enzymatic Basis of Detoxication. Enzymatic Basis of Detoxication
25
68
.
J.C. Ritchie, T.P. Sloan, J.R. Idle & R.L. Smith. 1980. Ciba Foundation Symposium 76 - Environmental Chemicals, Enzyme Function and Human Disease. Ciba Foundation Symposium 76 - Environmental Chemicals, Enzyme Function and Human Disease
219
244
.